Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.5 USD | -1.54% |
|
-0.09% | +0.35% |
07-10 | XOMA Corporation will Change its Name to XOMA Royalty Corporation | CI |
07-09 | Xoma Changes Name to Xoma Royalty | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.35% | 314M | - | ||
+20.17% | 126B | B+ | ||
+24.67% | 118B | B+ | ||
+24.13% | 27.87B | B | ||
-17.74% | 20.95B | B+ | ||
-14.94% | 16.92B | A- | ||
-15.21% | 16.18B | B | ||
+11.91% | 14.84B | C+ | ||
-47.10% | 14.79B | A- | ||
+54.50% | 14.08B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- XOMA Stock
- XOMAP Stock
- Ratings XOMA Royalty Corporation